![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjAg1pcTjSIhEHrWeN0PUTIjR7KZRByvynVvzBlK-d3z8BkMWGunMaoK8VWnstkAGd9rW0F22fcy-yShD8SiQTOguZbM0tPOOV0YYLiTPNsDjohKzvoHnWfDyAfnIshArn6ejIfupXT710/s320/fdagov_logo_type.gif)
Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release
The four manufacturers will make the Influenza A (H1N1) 2009 Monovalent vaccines using the established manufacturing processes for their seasonal influenza vaccines. FDA approved these vaccines as a strain change to each manufacturer’s seasonal influenza vaccine. There is considerable experience with seasonal influenza vaccine development and production and influenza vaccines produced by this technology have a long and successful track record of safety and effectiveness in the United States. The Influenza A (H1N1) 2009 Monovalent vaccines will undergo the usual testing and lot release procedures that are in place for seasonal influenza vaccines.
Lot release information will be updated weekly. Last update: 12/30/2009.
ABRIR AQUÍ:
Influenza A (H1N1) 2009 Monovalent Vaccines Composition and Lot Release
No hay comentarios:
Publicar un comentario